
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a preclinical stage biotechnology company with a solid pipeline of next-generation biopharmaceuticals that target hard-to-treat cancers and other chronic diseases. Using their proprietary AI technology and 3D-modeling, iBio aims to minimize downstream risks and decrease drug development timelines, potentially leading to increased success and revenue for the company. However, investors should be aware of potential risks including uncertainties surrounding the protection of iBio's intellectual property, the need for additional funding, and the clinical and regulatory risks associated with their product candidates.
Bears say
iBio is a preclinical biotech company with positive preclinical data on their antibody IBIO-610 and plans to file for regulatory approval soon, however, there is fierce competition in the space, potential need for future fundraising, and risks associated with their development pipeline and regulatory processes.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares